AZD2389

DB22104InvestigationalSmall molecule

AZD2389 is a small molecule fibroblast activation protein (FAP) inhibitor under investigation for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.

Mechanism: Pharmacologically active on Prolyl endopeptidase FAP
Curator reviewed
Code names: AZD2389

Resolves to

Targets

Q12884FAP

What you can answer from here — as of February 06, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with AZD2389, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account